ARTICLES BY LOUIS
“I’ve changed my perspective on this drug-substance/drug-product, end-to-end, ‘one-stop-shop’ services trend,” says Rick Panicucci, QED Therapeutics (a BridgeBio Pharma company). Even more, he's an idea of how to change CDMO consolidation dynamics to serve smaller drug sponsors.
“I learned the hard way,” says veteran biopharma executive, and current Senior Vice President CMC, QED Therapeutics, Rick Panicucci. “Even the best of outsourcing facilities won’t respect what you don’t inspect.” Months of COVID-19 lockdown could not dissuade him from living by his outsourcing canon. Here is how you can, too.
This gets filed in the scientific realm of: “Hey, look what we might have here?” A key ingredient for advanced, oral-solid-dose opioid medicines in clinical study, developed and manufactured with assistance from a reliable CDMO, turns out to have investigative potential for the treatment of COVID-19. Here’s how sponsor and service provider swung into action.
Why did GenVivo, a Southern California-based gene therapy developer, decide to establish its own facility, something not in their original strategy? “We had trouble outsourcing,” says Robert Johnson, COO and Scientific Advisory Board member. Not the first time we’ve heard this from a biopharma, but Johnson provides striking insight into the state of drug development and manufacturing outsourcing.
To learn more about the biopharma manufacturing training program at Thomas Jefferson University’s Jefferson Institute for Bioprocessing (JIB) in Philadelphia, I was sent to Los Angeles. Here’s what I learned there to help our readers facing challenges in recruiting skilled workers.
In part one - "Five Maxims For Outsourcing Success" - we tackled Lisa Wyman's first three of five tenets to better outsource by. Here we explore her belief that leveraging capabilities and capacities of CDMOs is predicated on an appetite for adaptability and flexibility, and that is exhibited as a quality of leadership.
“I’d say the paradigm has heavily shifted,” says Todd Mabe on his joining the ranks of other ex-Big Pharma moving to cell and gene therapy companies to drive build-buy decision-making, and manage both in-house and CDMO relationships. “In and Out Sourcing” we might start to call this advancing hybrid model.
"Outsourcing is really about positioning your CDMO to your competitive advantage," says Lis Wyman of Acceleron Pharma. That might just be the "maximum maxim" for outsourcing strategy. But Wyman has four more to offer, all enlightening to your craft of drug development and manufacturing.
“The outsourcing baseline for a biopharma is envisioning success, and putting together a well-defined package for the CDMO to get started and enabled to work independently and holistically throughout the product life cycle.” More insight into our provocative discussion on optimal outsourcing.
Pharma has a China problem. In at least one regard, it uncomfortably mirrors that of the media. But the media has (tentatively) begun a mea culpa of sorts. Should Pharma? An editorial on how Pharma has handled the (lack of a) Wuhan Coronavirus Lab investigation.